| Previous Close | 0.1076 |
| Open | 0.1060 |
| Bid | 0.0000 x 2900 |
| Ask | 0.0000 x 2200 |
| Day's Range | 0.1020 - 0.1900 |
| 52 Week Range | 0.1000 - 9.6600 |
| Volume | 48,269,395 |
| Avg. Volume | 7,182,147 |
| Market Cap | 7.027M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Heritage Global Partners, Inc. has agreed to purchase Achaogen’s lab equipment. Achaogen reached agreements with these purchasers, all of which remain subject to execution of binding definitive documents, following the conclusion of a structured auction held on June 3, 2019, at which these purchasers submitted the highest and best bids for these Achaogen assets. The binding definitive documents will be included in Achaogen’s Current Report on Form 8-K to be filed with the Securities and Exchange Commission following announcement of the execution of the documents.
Achaogen, Inc. (AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, announced today that it has filed a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the Court). Achaogen has also filed a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code. Achaogen has filed a series of motions with the Court seeking to ensure the continuation of normal operations during this process.
-- ZEMDRI’s once-daily 30-minute infusion facilitating usage in the outpatient setting -- -- Company’s recent restructuring aimed at conserving capital to continue assessment.
SOUTH SAN FRANCISCO, Calif., March 13, 2019 -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial.
Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the New England Journal of Medicine has published the results from the Phase 3 CARE (Combating Antibiotic Resistant Enterobacteriaceae) study of plazomicin in a Letter to the Editor. In this published study, the efficacy and safety of plazomicin versus colistin was evaluated in patients with serious bloodstream infections or hospital-acquired/ventilator-associated bacterial pneumonia caused by carbapenem-resistant Enterobacteriaceae (CRE). ZEMDRI® (plazomicin) is an aminoglycoside administered as a once-daily, 30-minute intravenous (IV) infusion that has activity against certain Enterobacteriaceae.
-- ZEMDRI is the only once-daily aminoglycoside therapy FDA-approved for use in complicated urinary tract infections (cUTI) -- -- Treatment with ZEMDRI resulted in a greater.
Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced the completion of its previously announced underwritten public offering of 15,000,000 shares of its common stock and accompanying short-term warrants to purchase up to 15,000,000 shares of its common stock and long-term warrants to purchase up to 15,000,000 shares of its common stock (collectively, the “warrants”). Each share of common stock was sold together with one short-term warrant to purchase one share of common stock and one long-term warrant to purchase one share of common stock, at a combined price to the public of $1.00 per share of common stock and accompanying warrants, for gross proceeds of $15.0 million and net proceeds of approximately $13.6 million after deducting underwriting discounts and commissions and estimated offering expenses payable by Achaogen.
-- Leerink February 27, 2019 at 9:30 a.m. ET -- -- Cowen March 12, 2019 at 12:00 p.m. ET -- SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 -- Achaogen, Inc. (NASDAQ: AKAO), a.
Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock and accompanying short-term warrants to purchase up to 15,000,000 shares of its common stock and long-term warrants to purchase up to 15,000,000 shares of its common stock (collectively, the “warrants”). Each share of common stock is being sold together with one short-term warrant to purchase one share of common stock and one long-term warrant to purchase one share of common stock, at a combined price to the public of $1.00 per share of common stock and accompanying warrants, for gross proceeds of $15 million, before deducting underwriting discounts and commissions and offering expenses payable by Achaogen.
Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Achaogen. In addition, Achaogen expects to grant the underwriter of the offering a 30-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.
Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it has responded to a Request for Information (RFI) regarding antibacterial products with the potential to treat resistant biothreat pathogens. The RFI was solicited by the Assistant Secretary for Preparedness and Response (ASPR) / the Biomedical Advanced Research and Development Authority (BARDA) under Project BioShield. The RFI specifically requested information on availabilities and capabilities for procuring, stockpiling and investing in the ongoing development of antibiotic products for commercial use for treatment of multiple biodefense indications, including pneumonic plague and tularemia, for which plazomicin has demonstrated preclinical efficacy.
Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today shared certain key preliminary unaudited results for the fourth quarter ended December 31, 2018, and provided an update on its commercial and corporate activities. “As our previously announced review of strategic alternatives continues, I am pleased with the steady progress of the ZEMDRI commercial launch and especially the commitment of the entire company to bringing this important medicine to the infectious disease community,” said Blake Wise, Achaogen’s Chief Executive Officer.
NEW YORK, NY / ACCESSWIRE / December 11, 2018 / Arcadia Biosciences and Achaogen were two winners in the biotech arena on Monday. Achaogen soared over 20% on positive clearance news for the Thermo Scientific QMS Plazomicin Immunoassay. There was no remarkable news from Arcadia Biosciences to explain the jump.
Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) has provided clearance for the Thermo Scientific QMS Plazomicin Immunoassay that provides a quantitative measure of plazomicin in human plasma using automated clinical chemistry analyzers. Results of the assay will be used to assist in the management of patients receiving plazomicin therapy. Plazomicin, marketed as ZEMDRI™ in the United States, was approved by the U.S. Food and Drug Administration for the treatment of adults with complicated urinary tract infections, including pyelonephritis, due to certain Enterobacteriaceae.
NEW YORK, Dec. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial.
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial.
-- Company provides update on ZEMDRITM commercialization and launch -- -- Conference call today at 8:30 a.m. Eastern Time -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2018 --.
Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it has begun a review of strategic alternatives to maximize shareholder value, including but not limited to the potential sale or merger of the Company or its assets. The Company also announced a restructuring of its organization to preserve cash resources which is expected to reduce operating expenses by approximately 35-40 percent, excluding one-time charges. “We are committed to evaluating strategic alternatives that enhance value for shareholders while maintaining our focus on the successful launch of ZEMDRI and the development of C-Scape as well as aggressively managing our operating expenses," said Blake Wise, CEO of Achaogen.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2018 -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial.